司美格鲁肽对无糖尿病肥胖患者心血管结局的影响
SELECT为多中心、双盲、随机、安慰剂对照、事件驱动优效性试验,纳入45岁及以上、已有心血管疾病、体质指数≥27且无糖尿病史的患者17,604例,1:1随机接受每周皮下司美格鲁肽2.4 mg或安慰剂。主要心血管终点为心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点(至首次事件分析)。平均随访39.8±9.4个月,司美格鲁肽组主要终点事件569/8803例(6.5%),安慰剂组701/8801例(8.0%)(HR 0.80;95%CI 0.72–0.90;P<0.001)。因不良事件永久停用试验药物者司美格鲁肽组1461例(16.6%),安慰剂组718例(8.2%)(P<0.001)。
要点
- 合并心血管疾病、超重或肥胖但无糖尿病者,每周皮下司美格鲁肽2.4 mg较安慰剂降低主要心血管复合终点(HR 0.80;95%CI 0.72–0.90;P<0.001)。
- 司美格鲁肽组主要终点事件6.5%(569/8803)vs 安慰剂组8.0%(701/8801),平均随访39.8±9.4个月。
- 因不良事件永久停用试验药物者司美格鲁肽组16.6%(1461例)vs 安慰剂组8.2%(718例)(P<0.001)。
- 平均暴露时间司美格鲁肽或安慰剂为34.2±13.7个月。
- 主要终点为心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点(至首次事件分析)。
适用人群与场景
- 45岁及以上、已有心血管疾病、体质指数≥27、无糖尿病史的患者。
处置流程与药物剂量
- 司美格鲁肽2.4 mg每周皮下注射一次,或安慰剂,1:1随机分组。
研究设计与关键结果
- 多中心、双盲、随机、安慰剂对照、事件驱动优效性试验,纳入17,604例患者,司美格鲁肽组8803例、安慰剂组8801例。
- 平均暴露时间司美格鲁肽或安慰剂为34.2±13.7个月,平均随访39.8±9.4个月。
- 主要心血管终点事件:司美格鲁肽组569/8803例(6.5%)vs 安慰剂组701/8801例(8.0%)(HR 0.80;95%CI 0.72–0.90;P<0.001)。
- 因不良事件永久停用试验药物:司美格鲁肽组1461例(16.6%)vs 安慰剂组718例(8.2%)(P<0.001)。
证据类型、等级与局限
- 多中心、双盲、随机、安慰剂对照、事件驱动优效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于已有心血管疾病、超重或肥胖但无糖尿病的患者,每周皮下司美格鲁肽2.4 mg在平均随访39.8个月时较安慰剂降低心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点发生率。
- 司美格鲁肽组因不良事件永久停用试验药物者比例高于安慰剂组(16.6% vs 8.2%,P<0.001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.
METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed.
RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).
CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
参考来源
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131. doi:10.1056/NEJMoa2307563
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。